Top Tech Companies in Boston, MA (4,875)

Strong Revenue Growth: Recent financials show accelerating top-line expansion, with quarterly revenue surpassing the billion-dollar mark and full-year results climbing meaningfully. Momentum continued into 2026, reflecting broad demand across observability, security, and AI-related offerings.

Healthy Cash Flow: Operations are generating substantial operating and free cash flow alongside growth. This pattern persisted through mid-2026, indicating efficient scaling.

Strong Market Position & Advantage: Industry evaluations repeatedly place the company as a Leader in observability and digital experience monitoring, including top positioning for execution. Recognition such as Customers’ Choice and multi-product leadership suggests deep adoption and competitive strength.

Strong Revenue Growth: Revenue is growing at double-digit rates, with Q2 2026 up 27% year over year and first-half 2026 up about 25%. Management also raised full-year 2026 guidance to $94–96 million, implying approximately 22–24% growth.

Market Expansion: U.S. activity accelerated, with U.S. analysis volume up 60% year over year in Q2 2026 and major health-system additions. Core genomics customers increased to 542 as of June 30, 2026, from 490 a year earlier.

Customer Loyalty & Retention: Net dollar retention improved to 117% in Q2 2026 (versus 107% a year earlier), indicating greater spending within the installed base. Platform usage also reached a record 115,000 analyses in Q2 2026, up 22% year over year.

Investor Backing & Capital Strength: Evidence indicates a $50 million Series D in April 2026 led by Boehringer Ingelheim, following a Series C in March 2025. This ongoing capital access, including dedicated commercialization funding, signals strong financial support for the next phase of growth.

Strategic Partnerships: Evidence indicates deep relationships with Boehringer Ingelheim and Otsuka, alongside new collaborations such as Ultrahuman for migraine-related technology. These alliances are described as enabling development, regulatory progress, and commercialization pathways across multiple programs.

Product Line Growth: Evidence indicates multiple FDA milestones—Rejoyn for major depressive disorder symptoms (2024), CT-132 for episodic migraine prevention (2025), and Motivista/CT-155 for negative symptoms of schizophrenia (2026)—plus expansion into obesity and cardiometabolic disease via acquired assets. These developments broaden the portfolio across therapeutic areas and advance late-stage candidates toward market.

Strong Revenue Growth: Net revenue rose 16% in 2025 and increased 14% year over year in Q2 2026, alongside gains in gross dollar volume, cross-border volume, and switched transactions. Feedback suggests this growth spans both the core network and international activity.

Profitability: Operating income and net income grew faster than revenue in Q2 2026 (operating income +17%, net income +19%), with full-year 2025 also showing double-digit profit increases. These results indicate operating leverage and earnings expansion alongside sales growth.

Diversified Revenue Streams: Value-added services and solutions grew roughly 18%–23% in recent periods and now comprise a substantial share of total revenue, including cybersecurity, fraud prevention, authentication, and analytics. This broadens the business beyond card transactions and supports continued expansion.

Strong Revenue Growth: Revenue has scaled to over $1.2B with continued double-digit quarterly increases and an outlook nearing $1.5B, indicating sustained momentum. Guidance increases reinforce the trajectory of ongoing top-line expansion.

Market Expansion: International revenue is growing faster than the overall business and now represents a significant share of total revenue, with customers across more than 100 countries. The customer base surpassing 205,000 underscores broader geographic reach and upmarket penetration.

Customer Loyalty & Retention: Net revenue retention remains above 100%, suggesting existing customers are expanding spend through cross-selling and wider platform adoption. Larger-account cohorts are growing rapidly, including rising counts of $50K+ and $1M+ ARR customers.

Profitability: Profitability is improving markedly, with net income and underwriting results rising and a strong combined ratio in early 2026. Lower catastrophe losses and stronger investment income also supported these gains.

Investor Backing & Capital Strength: Capital strength is solidifying as equity increased and S&P upgraded core operating companies’ financial strength ratings to A+, citing improved underwriting and capitalization. This positions the company to pursue growth from a stronger balance sheet.

Future-Ready Strategy: Strategy is shifting from “fixing” to “building,” emphasizing selective, profitability-threshold growth in segments showing momentum like Global Risk Solutions. Management highlights disciplined expansion rather than growth at any cost.

Market Expansion: Customer reach is described as rising from about 1,100 districts in 2021 to more than 1,900, with coverage across 50+ states and 2.5 million+ learners. Feedback suggests this broadened footprint indicates ongoing expansion in its core K–12 niche.

Product Line Growth: The launch of Ellevation Benchmark in January 2026 and added analytics/compliance capabilities extend the platform beyond program management into assessment and integrated workflows. Feedback suggests this creates opportunities to deepen adoption within existing districts and attract new ones.

Investor Backing & Capital Strength: Ownership by Curriculum Associates since 2021 is presented as adding financial, operational, and distribution support. Feedback suggests this backing underpins continued investment in hiring, product development, and commercial roles.

Investor Backing & Capital Strength: Capital raising includes a $372 million Series D in 2024 with participation from Sanofi, bringing total funding above $600 million. The stated use of proceeds was to expand the drug pipeline and AI platform, indicating a strong financial base for growth.

Product Line Growth: The portfolio has expanded through multiple in-licensing deals in 2025–2026 and now spans preclinical, Phase 1, and Phase 2 programs. Tangible execution includes dosing the first participant in the BLKR201 Phase 1 trial in June 2026, only months after licensing the asset.

Strategic Partnerships: High-profile collaborations include work with Sanofi and OpenAI to build AI tools for drug development, alongside a Sanofi licensing agreement for gusacitinib with significant potential milestone value. These relationships reinforce external validation and create pathways to scale development.

Investor Backing & Capital Strength: Evidence highlights a $200 million Series C in July 2024 at a $1 billion valuation with participation from prominent investors, indicating substantial capacity to fund expansion. While valuation alone does not confirm revenue growth, the capital base supports continued scaling.

Market Expansion: Adoption appears to be widening across major logistics providers and governments, including an expanded CBP contract, a UK government program, FedRAMP High authorization, and reported daily use by more than 5,000 CBP agents. Partnerships such as Maersk and work with multiple governments suggest broader reach across sectors and geographies.

Product Line Growth: The July 2026 acquisition of Cervo AI extends capabilities from supply-chain intelligence into automated customs-entry workflows. Additional deployments like Product Passports and tariff tools indicate a deepening and broadening of the offering.

Strong Revenue Growth: Recent results show revenue up 27.2% year over year in Q2 2026, with full-year 2025 revenue rising 26.6% to $623 million. Management also raised its 2026 growth outlook, reinforcing the trajectory.

Market Expansion: Client additions of 200+ across 45 countries in both Q1 and Q2 2026 and growth beyond education into travel, healthcare, and B2B indicate a broadening footprint. Education revenue outside core markets growing 30%+ further supports geographic expansion.

Profitability: Adjusted EBITDA increased 44.5% in Q2 2026 with margin expansion, and full-year 2025 reported positive net income. These trends suggest improving earnings power alongside scale.

Strong Revenue Growth: Annual revenue rose from $3.67B in 2023 to $6.05B in 2025, and management guides to $6.5–$6.9B for 2026. This multi-year trajectory signals substantial top-line expansion despite quarterly volatility.

Market Expansion: The sportsbook operates in 30 states, Washington, D.C., Puerto Rico, and parts of Canada. Broader geographic access supports continued user and wagering growth.

Diversified Revenue Streams: Sportsbook, iGaming, and the newer Predictions offering provide multiple growth avenues. iGaming revenue grew 7.5% year over year in Q2 2026, while Predictions launched in December 2025 as another channel.

Strong Revenue Growth: Reported bookings and subscription revenue more than doubled in 2025, indicating accelerating commercial scale. Membership expanded into the millions by mid-2026, reinforcing top-line momentum.

Market Expansion: International membership surged and the company broadened distribution into retail, wholesale, and enterprise channels, extending growth beyond direct-to-consumer. Positioning widened from elite athletes to everyday health, sleep, and longevity use cases.

Investor Backing & Capital Strength: A substantial Series G at a markedly higher valuation brought significant capital from institutional and strategic investors. The raise supported planned headcount expansion and continued product development.

Profitability: Operating and net income remained positive even as revenue softened in recent quarters. This indicates an earnings base that is holding up during a period of slower demand.

Healthy Cash Flow: Free cash flow stayed positive with meaningful generation quarter to quarter, and guidance points to continued cash production. Liquidity is reinforced by a sizable balance of cash, cash equivalents, and government securities.

Future-Ready Strategy: Management is concentrating investment on the Command Platform, detection and response, exposure management, and AI-enabled security operations. This refocus aims to position the portfolio for a return to growth once the transition progresses.

Strong Revenue Growth: Revenue has been accelerating on a quarterly basis, and full-year guidance was raised, reflecting sustained top-line momentum. Contracted demand indicators also point to continued near-term growth.

Market Expansion: Enterprise penetration is deepening with record additions of large customers and a notable footprint among major corporate ecosystems and top global websites. The customer mix is shifting upmarket, signaling successful movement into higher-value segments.

Innovation-Driven Growth: Adoption of Workers, Zero Trust, and AI-related workloads is highlighted as a key catalyst expanding use of the platform. Product breadth across security, developer services, and edge computing is supporting multi-product growth.

Strong Revenue Growth: ARR is reported to have more than tripled between 2021 and 2025 while profitability improved. AI-related ARR also rose from $20 million in Q1 2025 to $109 million in Q1 2026, reinforcing momentum.

Market Expansion: Reported enterprise customers grew from 1,200+ in 2024 to 1,500+ in 2025, and platform reach expanded from 15 million to 25 million endpoints/employees. International moves, including plans for Japan and South America, indicate continued geographic expansion.

Investor Backing & Capital Strength: A majority investment by Vista Equity Partners at an approximately $3 billion valuation in 2025 signals strong external confidence. This transaction follows years of scaling and provides capital support for the next phase.

Market Expansion: Company disclosures indicate a larger commercial footprint, with the enterprise customer count rising from 600+ in 2022 to 900+ by 2026 alongside a broadened partner network. Momentum in the United States is highlighted as particularly strong, with leadership hires pointing to continued geographic focus.

Product Line Growth: Recent moves such as the PricingHUB acquisition and the introduction of agentic AI capabilities point to an expanded platform spanning product information, pricing, and AI-enabled commerce. Product activation reach has also widened to hundreds of destinations, signaling broader use cases and distribution.

Strong Market Position & Advantage: Industry recognition includes being named a Leader in Gartner’s 2026 Magic Quadrant for PIM, supported by additional analyst validations across recent years. Such positioning suggests competitive strength in a category with rising demand for structured product data.

Investor Backing & Capital Strength: A $27M Series B round in August 2025 led by Northzone, alongside prior seed and Series A funding, indicates substantial capital support to accelerate product and go-to-market efforts. This progression signals strong investor confidence in the company’s expansion plans.

Market Expansion: The platform is described as serving home-service professionals across all 50 U.S. states and reports more than 6,000 small businesses using its solutions. Company materials also note a rise in cumulative customer booked revenue from $655M+ to $1.2B+, suggesting broader reach and usage.

Innovation-Driven Growth: New AI capabilities—including an app and the ‘Sidekick’ assistant for calls, follow-ups, quotes, and payments—extend the product beyond websites into day-to-day operations. Ongoing investment in AI features supports deeper adoption and potential future monetization.

Strong Revenue Growth: Reported three-year revenue growth of 1,061% and placement on the 2026 Inc. 5000 underscore rapid top-line expansion. While absolute revenue is not disclosed, the growth trajectory across 2022–2025 is clearly strong.

Investor Backing & Capital Strength: An $80 million Series C in April 2026, bringing total funding above $160 million and a reported $955 million valuation, signals substantial capital support. Participation from established investors and continued financing provide resources for expansion.

Market Expansion: Customer count reportedly grew from more than 200 in 2024 to over 500 by 2026, including 16 of the top 20 MedTech companies. This indicates broadening adoption across both emerging firms and large enterprises.

Product Line Growth: Expansion into exchange-traded funds began in 2024 with eight active ETFs by year-end 2025 and further launches in 2026, while fixed-income offerings are identified as attracting inflows. ETF assets exceeded about $1.4 billion at year-end 2025 with roughly $1.2 billion in net inflows since launch, though still small relative to firmwide AUM.

Profitability: Underlying net income rose modestly year over year in Q2 2026 and the pre-tax operating margin improved to around 35.7%. These signals indicate earnings resilience despite pressure on client flows.

Strong Brand Reputation: Independent research maintained a High Parent Rating and highlighted a patient, long-term investment culture and team stability. A century-long history and substantial global scale reinforce organizational credibility.

Strong Revenue Growth: Square’s segment revenue increased 10% in 2025 and rose 16% year over year in Q2 2026, pointing to renewed topline momentum. These gains accompany rising seller activity and broader ecosystem adoption.

Profitability: Gross profit reached about $1.16 billion in Q2 2026, up 13% year over year, after a 9% increase for full-year 2025. The trend indicates improving economic contribution from processing, software, and financial services.

Market Expansion: International GPV grew 28% year over year in Q2 2026 while U.S. GPV rose 10%, alongside traction with larger merchants and vertical solutions such as restaurants and banking. These patterns suggest widening geographic and segment reach.